In patient-derived xenografts, we previously found that CDK4/6 inhibition was highly effective at limiting tumor growth, and had a profound impact on the proliferative index.13 This finding was also recapitulated in the analysis of primary tumor explants. The gene discussed is CDK4; the disease is neoplasm.